Endo Health Solutions, a U.S.-based specialty healthcare company, will acquire privately-held Boca Pharmacal, a specialty generics company, for $225 million in cash. Boca Pharmacal focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions.

The transaction is expected to be immediately accretive to Endo's 2013 adjusted diluted earnings per share. Boca Pharmacal is expected to generate EBITDA of approximately $50 million in full year 2013. The deal shoul close before year end.